Information Provided By:
Fly News Breaks for February 5, 2020
LLY
Feb 5, 2020 | 16:50 EDT
Mizuho analyst Vamil Divan initiated coverage of Eli Lilly with a Neutral rating and $148 price target. The analyst notes that the company's Trulicity and Taltz remain as its key drivers of top and bottom-line growth, though he also expects the impact of Verzenio to be greater after the recent positive data releases. Divan adds that the acquisition of Loxo should provide an incremental medium-term growth driver, but even when accounting for all of those positives in his model, his derived valuation remains close to the current stock price.